A5089760716- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Cancer-related cognitive impairment studies
- Management of metastatic bone disease
- Angiogenesis and VEGF in Cancer
- Cholinesterase and Neurodegenerative Diseases
- Biochemical Acid Research Studies
- Gastric Cancer Management and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer Cells and Metastasis
- Intraperitoneal and Appendiceal Malignancies
- Breast Lesions and Carcinomas
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Polymer Nanocomposite Synthesis and Irradiation
- Endometrial and Cervical Cancer Treatments
- Cancer-related Molecular Pathways
- Nanoparticle-Based Drug Delivery
- Cardiovascular Syncope and Autonomic Disorders
- Adenosine and Purinergic Signaling
Ospedale di Livorno
2007-2024
Azienda Usl Toscana Centro
2017-2023
Lega Italiana per la Lotta ai Tumori
2014-2018
Istituto Oncologico Veneto
2018
ASST Fatebenefratelli Sacco
2018
Istituti di Ricovero e Cura a Carattere Scientifico
2018
Ospedale Policlinico San Martino
2018
University of Pisa
2007-2009
Associazione Italiana Di Oncologia Medica
2005
The combination of a triple-drug chemotherapy regimen with an anti-epidermal growth factor receptor (EGFR) agent as first-line treatment metastatic colorectal cancer (mCRC) showed promising activity along safety concerns in single-arm phase 2 trials. role maintenance following and anti-EGFR the optimal to be adopted are not established.To evaluate cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) explore or bevacizumab RAS BRAF wild-type mCRC.In prospective, noncomparative, open-label,...
Several studies have evaluated cardioprotective strategies to prevent myocardial dysfunction in patients who are receiving cardiotoxic therapies. However, the optimal approach still represents a controversial issue.To determine whether pharmacological cardioprevention could reduce subclinical heart damage with breast cancer being treated anthracycline-based chemotherapy.The SAFE trial was 4-arm, randomized, phase 3, double-blind, placebo-controlled, national multicentric study conducted at 8...
// Anna Solini 1 , Vittorio Simeon 2 Lisa Derosa 3 Paola Orlandi Chiara Rossi Andrea Fontana Luca Galli Teresa Di Desidero Fioravanti Sara Lucchesi 4 Luigi Coltelli Laura Ginocchi Giacomo Allegrini Romano Danesi Alfredo Falcone Guido Bocci Department of Clinical and Experimental Medicine, University Pisa, Italy Laboratory Pre-clinical Translational Research, IRCCS - CROB Referral Cancer Center Basilicata, Rionero in Vulture, Potenza, Oncology Unit 2, Hospital Division Medical Oncology,...
Abstract Background Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group Geriatric Oncology) was designed to assess efficacy and tolerability eribulin, according parameters usually used geriatric oncology. Subjects, Materials, Methods An observational conducted on 50 consecutive patients with The primary...
Aim: To investigate pharmacogenetic interactions among VEGF-A, VEGFR-2, IL-8, HIF-1α, EPAS-1 and TSP-1 SNPs their role on progression-free survival in a population of metastatic breast cancer patients treated with bevacizumab combination first-line paclitaxel. Patients & methods: Analyses were performed germline DNA obtained from blood samples investigated by real-time polymerase chain reaction technique. The multifactor dimensionality reduction methodology was applied to the interaction...
Abstract To investigate pharmacogenetic interactions among VEGF-A , VEGFR-2 IL-8 HIF-1α EPAS-1 and TSP-1 SNPs their role on progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with bevacizumab plus first-line paclitaxel or alone. Analyses were performed germline DNA, investigated by real-time PCR technique. The multifactor dimensionality reduction (MDR) methodology was applied to the interaction between SNPs. present study an explorative, ambidirectional cohort...
Recent data reported an association between VEGF-A genotype of tumors and median overall survival as well grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer. In the present case we report a discordant tumor normal tissue patient with responsive hepatic lesion chemoresistant cancer treated paclitaxel. Moreover, show that, despite very low protein expression, neoplastic was vascularized responded to therapy. The discordance polymorphisms germline DNA may suggest...
Ribociclib plus an aromatase inhibitor and ovarian function suppression is the preferred first-line option for pre-/perimenopausal women with hormone receptor-positive/human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer. We opened italian managed access program (MAP) that permitted to ribociclib selected patients allowed collect informative results on clinical impact of therapy. The MAP (April 2018–May 2020) included 64 premenopausal patients,...
Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2−) advanced breast cancer (ABC) the Phase 3b CompLEEment-1 trial. To evaluate of ribociclib Italian subpopulation with HR+, HER2− ABC from Patients received (600 mg/day, 3 weeks on/1 week off) (2.5 mg/day) while men premenopausal women additionally goserelin. were allowed ≤ 1 line prior chemotherapy an Eastern Cooperative...
Abstract BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) represent the standard of care for hormone receptor-positive (HR+)/Human Epidermal Growth Factor 2 negative (HER2-) metastatic breast cancer (MBC); no consensus actually exists second-line (2L) treatments. The HERMIONE-13 trial evaluates adopted therapeutic options after CDK4/6i failure and potential factors that influence these choices. METHODS: is a retrospective prospective multicentric observational involving 15...
870 Background: Gemcitabine (G) and Capecitabine (C) are both actives in metastatic breast cancer (MBC). Methods: To define the maximum tolerated dose of this combination we designed a phase I study with escalating G (from 750 mg/m2 up to 1500 increments 250 mg/m2) at day 1 8 every 3 weeks combined C 2000 mg/m2/die on days 14. better investigate activity toxicity recommended doses, II has been subsequently performed patients (pts) pre-treated anthracyclines taxanes. Results: 12 pts have...
Abstract Introduction. Several studies have evaluated cardioprotective strategies to prevent myocardial dysfunction in patients who are receiving cardiotoxic therapies. Angiotensin-converting enzyme inhibitors and β-blockers recommended first-line agents for heart failure. However, the optimal approach still represents a controversial issue. We hypothesized whether pharmacological cardioprevention could reduce subclinical damage with breast cancer being treated an anthracycline-based...
e13064 Background: The introduction in the clinical practice of CDK4 / 6 inhibitors, combination with endocrine therapy, has been a breakthrough therapeutic scenario hormone receptor+ve/Human Epidermal growth Factor 2–ve (HR+/HER2–) MBC pts. However, despite outstanding results terms OS and quality life achieved up to now, it is important consider that highly selected population trials doesn’t always accurately predict impact therapies general population, hence having real world data an...
Abstract Background: Around 20% of breast cancers (BC) are HER-2+. Trastuzumab (T) has dramatically changed the outcome HER-2+ BC patients (pts), both in early and advanced settings. The combination Pertuzumab (P) plus T docetaxel, used as first-line treatment for metastatic (MBC) phase III CLEOPATRA study, significantly prolonged progression free survival (PFS) overall (OS). In order to verify results Cleopatra trial unselected pts, we performed a multicenter, retrospective-prospective,...
Abstract Background: several studies have evaluated cardioprotective strategies to prevent myocardial dysfunction in patients receiving cardiotoxic therapies. However, the optimal approach still represents a controversial issue. The SAFE trial (ClinicaTrials.gov identifier: NCT2236806) is four-arm, randomized, phase 3, double-blind, placebo-controlled study. objective determine whether pharmacological cardioprevention could reduce subclinical heart damage breast cancer treated with...
1086 Background: Previous retrospective studies have attempted to identify a possible role of VEGF single nucleotide polymorphisms (SNPs) predict BV efficacy in terms OS and PFS MBC pts with conflicting results (Schneider 2008, Grimaldi 2011, Lambrechts 2011). Methods: On the basis these preliminary data, we decided assess population if different VEGF, VEGFR-2, IL-8, IL-6, HIF-1alfa, EPAS-1 TSP-1 genotypes could first line + paclitaxel (P) response both PFS. Analyses were performed on...
Abstract Background: In the era of targeted therapies, chemotherapy (CT) is still a valuable treatment option for patients (pts) with HER2 negative metastatic breast cancer (MBC). The identification predictive and prognostic markers might improve response survival. Here we investigated role tumor subtypes, circulating cells (CTCs), mutations in genes or pathways interest, predicting to CT prognosis MBC pts within AARES trial. Methods: an open label multicentric randomised phase 2 trial...